Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism

Aman, Michael G., Arnold, M.D., L. Eugene, McDougle, Christopher J., Vitiello, Benedetto, Scahill, Lawrence, Davies, Mark, McCracken, James T., Tierney, Elaine, Nash, Patricia L., Posey, David J., Chuang, Shirley, Martin, Andres, Shah, Bhavik, Gonzalez, Nilda M., Swiezy, Naomi B., Ritz, Louise, Koenig, Kathleen, McGough, James, Ghuman, Jaswinder K., Lindsay, Ronald L.·2005·Journal of Child and Adolescent Psychopharmacology

Abstract

Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0.5-3.5 mg/day) in 101 children and adolescents with a lifetime diagnosis of autistic disorder. In addition, 37 placebo nonresponders received open-label risperidone for another 8 weeks. Of all the risperidone responders (n=65), 63 entered an open extension of another 16 weeks (6 months total risperidone exposure), and 32 of them were rerandomized to either continued risperidone therapy (n=16) or gradual replacement with placebo (n=16) over 8 weeks. We collected the following measures of safety and tolerability: (1) laboratory blood assessments (CBC with differential, electrolytes, and liver function tests) and urinalyses, (2) vital signs, (3) Side Effects Review of AEs thought to be associated with risperidone, (4) sleep records, (5) Simpson Angus Neurological Rating Scale (SARS), (6) Abnormal Involuntary Movement Scale (AIMS), and (7) height and weight. No clinically significant changes were found on the lab tests. During the 8-week acute trial, the most common AEs on the Side Effects Review, scored as moderate or higher, were as follows (placebo and risperidone, respectively): Somnolence (12% and 37%), enuresis (29% and 33%), excessive appetite (10% and 33%), rhinitis (8% and 16%), difficulty waking (8% and 12%), and constipation (12% and 10%). "Difficulty falling asleep" and anxiety actually favored the risperidone condition at statistically significant levels. The same AEs tended to recur through 6 months of treatment, although often at reduced levels. Using Centers for Disease Control (CDC) standardized scores, both weight and body mass index (BMI) increased with risperidone during the acute trial (0.5 and 0.6 SDs, respectively, for risperidone; 0.0 and 0.1 SDs, respectively, for placebo) and into open-label extension (0.19 and 0.16 SDs, respectively), although the amount of gain decelerated with time. Extrapyramidal symptoms, as assessed by the SARS, were no more common for drug than placebo, although drooling was reported more often in the risperidone group. There were no differences between groups on the AIMS. Two subjects had seizures (one taking placebo), but these were considered unrelated to active drug. Most AEs were mild to moderate and failed to interfere with therapeutic changes; there were no unanticipated AEs. The side effects of most concern were somnolence and weight gain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2005.15.869

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 170

Metadata

Authors
Aman, M. G., Arnold, M. D., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., Chuang, S., Martin, A., Shah, B., Gonzalez, N. M., Swiezy, N. B., Ritz, L., Koenig, K., McGough, J., Ghuman, J. K., & Lindsay, R. L.
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2005-12
Volume
15
Issue
6
Pages
869-884
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W1983061090
Cited by
170
References
3
FWCI
4.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. https://app.cochat.ai/papers/10.1089/cap.2005.15.869
The paper
Aman, M. G., Arnold, M. D., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., Chuang, S., Martin, A., Shah, B., Gonzalez, N. M., Swiezy, N. B., Ritz, L., Koenig, K., McGough, J., Ghuman, J. K., & Lindsay, R. L. (2005). Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2005.15.869

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.